Treatment stores

This Shawnee woman has been cancer-free for 7 years after a treatment that was just approved by the FDA

After two years of battling an aggressive form of cancer, Emily Dumler beat it in just five minutes.

What do you want to know

• Emily Dumler, a Shawnee mother of three, was the third person in the world to complete a breakthrough treatment for B-cell lymphoma, an aggressive form of cancer.

• Yescarta, a brand of the breakthrough immunotherapy treatment called CAR T-cell therapy, just received FDA approval to treat more cancer patients like Dumler

• Emily Dumler is now using her story to encourage other cancer patients who now have access to this form of cell therapy

Dumler was first diagnosed with B-cell lymphoma, a cancer that begins in the lymphatic system, nearly a decade ago.

In 2015, the Shawnee mother of three had six months to live after a brutal stem cell transplant failed to heal her body during another intense round of chemotherapy.

Emily Dumler underwent at least two rounds of chemotherapy, but her body failed to respond to the intense treatment, leaving her six months to live. Photo courtesy of Emily Dumler.

That’s when she entered a clinical trial for a new immunotherapy treatment that would make her the third person in the world to complete the diet.

Now, years later, she sees that other cancer patients can benefit from the treatment she says saved her life.

This CAR-T cell therapy with the brand name Yescarta just received approval on Friday from the United States Food and Drug Administration to treat more patients like her.

“Of course it gave me my life back,” Dumler said, “but knowing now that patients can a) have hope for a future, and b) be able to bypass another treatment – which means just, you know, another six months of horrendous side effects – just to shorten the duration of treatment, it’s amazing how far it has gone and that so many patients can access it so much more easily.

Directed by Kiteowned by pharmaceutical giant Gilead, Yescarta designs a patient’s blood to treat their cancer.

According to Kite, it is the first and only FDA-approved CAR T-cell therapy to treat patients who relapse or fail to respond to their first cycle of chemotherapy.

Emily Dumler lives with her family in Shawnee. From left to right, Bella, Emily, Scott, Hudson and Lola. Photo courtesy of Emily Dumler.

“Today’s FDA approval brings that hope to more patients by enabling the power of CAR T-cell therapy to be used earlier in the treatment journey,” said Christi Shaw, Chief Executive Officer of Kite. “This stage took years to prepare.”

Initially diagnosed with a bleeding disorder in August 2013 that led to months of hospitalization and the discovery of lymphoma, Dumler participated in the CAR T-cell therapy clinical trial in July 2015.

At the time, she was three months into her six-month life expectancy. His body was weak and had several pounds less due to chemotherapy.

The clinical trial lasted five minutes and Dumler was monitored for nine days with difficult side effects including high heart rate, low blood pressure and some cognitive issues.

However, a CT scan a month later showed no signs of cancer.

This year, Dumler is celebrating seven years without cancer. And today, she continues to share her story with other patients who need encouragement and options.

“Everything I was doing right now, I had no idea what it meant, other than wanting to be alive for my kids, and looking back, I know I’m a pioneer,” said Dumler said. “I never thought I would be a person who would have an important role that seems so important, but really, I have been able to talk to so many patients now who have been through it or are preparing to undergo the same treatment. , and just giving them my personal experience, encouraging them, answering their questions. I now understand why I am still here.